Changes in Phenotypic and Molecular Features of Naïve and Central Memory T Helper Cell Subsets following SARS-CoV-2 Vaccination
- PMID: 39340069
- PMCID: PMC11435719
- DOI: 10.3390/vaccines12091040
Changes in Phenotypic and Molecular Features of Naïve and Central Memory T Helper Cell Subsets following SARS-CoV-2 Vaccination
Abstract
Molecular changes in lymphocytes following SARS-CoV-2 vaccination are incompletely understood. We hypothesized that studying the molecular (transcriptomic, epigenetic, and T cell receptor (TCR) repertoire) changes in CD4+ T cells following SARS-CoV-2 vaccination could inform protective mechanisms and refinement of future vaccines. We tested this hypothesis by reporting alterations in CD4+ T cell subsets and molecular features of CD4+ naïve and CD4+ central memory (CM) subsets between the unvaccinated and vaccinated groups. Compared with the unvaccinated, the vaccinated had higher HLA-DR expression in CD4+ T subsets, a greater number of differentially expressed genes (DEGs) that overlapped with key differentially accessible regions (DARs) along the chromatin linked to inflammasome activation, translation, regulation (of apoptosis, inflammation), and significant changes in clonal architecture beyond SARS-CoV-2 specificity. Several of these differences were more pronounced in the CD4+CM subset. Taken together, our observations imply that the COVID-19 vaccine exerts its protective effects via modulation of acute inflammation to SARS-CoV-2 challenge.
Keywords: CD4+ T helper cell; COVID-19; SARS-CoV-2; T cell receptor; epigenetics; repertoire; transcriptomics; vaccination.
Conflict of interest statement
LE reported receiving grants from the National Institute for Health Research and European Union Horizon 2020. MSH reports receiving a grant from the Chief Scientists Office, Scotland, for time-critical precision medicine in adult critically ill patients (TRAITS Programme—
Figures





Similar articles
-
Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing.Emerg Microbes Infect. 2023 Dec;12(1):e2187245. doi: 10.1080/22221751.2023.2187245. Emerg Microbes Infect. 2023. PMID: 36987861 Free PMC article.
-
Immune Response to SARS-CoV-2 Vaccine in 2 Men.Int Arch Allergy Immunol. 2022;183(3):350-359. doi: 10.1159/000520046. Epub 2021 Nov 18. Int Arch Allergy Immunol. 2022. PMID: 34794147 Free PMC article.
-
Characterization of SARS-CoV-2 public CD4+ αβ T cell clonotypes through reverse epitope discovery.bioRxiv [Preprint]. 2021 Nov 22:2021.11.19.469229. doi: 10.1101/2021.11.19.469229. bioRxiv. 2021. Update in: Cell Rep Med. 2022 Aug 16;3(8):100697. doi: 10.1016/j.xcrm.2022.100697. PMID: 34845450 Free PMC article. Updated. Preprint.
-
The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection.Front Immunol. 2022 Jun 27;13:904686. doi: 10.3389/fimmu.2022.904686. eCollection 2022. Front Immunol. 2022. PMID: 35833134 Free PMC article. Review.
-
Chronic Immune Activation and CD4+ T Cell Lymphopenia in Healthy African Individuals: Perspectives for SARS-CoV-2 Vaccine Efficacy.Front Immunol. 2021 Jun 17;12:693269. doi: 10.3389/fimmu.2021.693269. eCollection 2021. Front Immunol. 2021. PMID: 34220854 Free PMC article. Review.
References
-
- Folegatti P.M., Ewer K.J., Aley P.K., Angus B., Becker S., Belij-Rammerstorfer S., Bellamy D., Bibi S., Bittaye M., Clutterbuck E.A., et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478. doi: 10.1016/S0140-6736(20)31604-4. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous